摘要
目的探讨大剂量环磷酰胺(CTX)治疗难治性成人Still病(adult-onset still's disease,AOSD)的可行性、有效性及安全性.方法对3例常规治疗效果不佳的难治性AOSD病患者进行大剂量CTX治疗,总量3.6～6 g,分3～4周给药.观察3例患者治疗前后的临床转归和实验室改变.结果3例难治性AOSD患者经过CTX化疗后,2例随访18个月,1例随访12个月,实验室指标恢复正常,病情缓解,且3例患者均对大剂量CTX耐受性良好,无严重不良反应发生.结论大剂量CTX对此3例难治性AOSD治疗安全可行,且临床症状完全缓解,如何选择合适的病例尚待进一步探讨.大剂量CTX能否使病情长期缓解尚有待于更多临床病例的观察及更长时间的临床随访.
Objective To study the feasitility,efficacy,and safety of high-dose cyclophosphamide(CTX)chemotherapy for refractory adult-onset Still's disease(AOSD).Methods Three patients with refractory AOSD received the treatment of high-dose CTX.CTX were chosen for high-dose chemotherapy within three or four weeks,total dosage was 3.6-6 g.The features of clinical manifeslation and lab findings before and after the treatment were compared.Results All of three patients achieved complete remission for 12 to 18 months of follow-up.The lab findings associated with disease were normal and disease was alleviated.High-dose CTX was well tolerated and there were no severe side effects.Conclusion High-dose CTX chemotherapy is feasible and safe in these three refractory AOSD patients,it induced complete remission in them.But it is very important to select refractory AOSD patients,and it need more patients and longer follow-up period to know whether using high-dose CTX can release the disease for a long time.
出处
《福建医药杂志》
CAS
2005年第1期3-4,共2页
Fujian Medical Journal
